• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1990年至2021年欧洲地区肝癌负担:全球疾病负担研究的子分析

Burden of liver cancer in the European region from 1990 to 2021: a sub-analysis of the global burden of disease study.

作者信息

Kazi Onika, Hamidzadeh Shokoufeh, Ehsani Zunuz Babak, Khordoo Abdolsabour, Mazloomi Seyede Saba, Khademsedaghat Hossein, Khadembashiri Mohammad Amin

机构信息

School of Medicine, Shahid Beheshti University of Medical University, Tehran, Iran.

Department of Internal Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Ann Med Surg (Lond). 2025 May 30;87(7):4053-4065. doi: 10.1097/MS9.0000000000003433. eCollection 2025 Jul.

DOI:10.1097/MS9.0000000000003433
PMID:40851944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12369744/
Abstract

BACKGROUND

Liver cancer is one of the leading causes of cancer-related deaths worldwide. In Europe, viral hepatitis, alcohol consumption, and metabolic diseases contribute to this burden. Using data from the Global Burden of Disease Study 2021, we report here the liver cancer epidemiology in Europe between 1990 and 2021, describing recent trends, geographical disparities, and the major risk factors influencing disease outcomes.

METHODS

The Global Burden of Disease Study 2021 provided standardized data on liver cancer incidence, mortality, and disability-adjusted life years (DALYs) across Europe from 1990 to 2021, utilizing advanced statistical modeling tools like DisMod-MR 2.1 to ensure accuracy and comparability. Age-standardized rates (age-standardized incidence rate, ASIR; age-standardized mortality rate (ASMR); and age-standardized DALYs rate, ASDR) were analyzed alongside the socio-demographic Index (SDI) to evaluate trends, regional disparities, and associations using joinpoint regression and LOESS modeling. Data visualization involved Python tools, including choropleth maps and regression plots.

RESULTS

Liver cancer burden in Europe has increased significantly, with the ASIR rising from 3.04 [2.93-3.14] in 1990 to 4.20 [3.93-4.40] in 2021, the ASMR increasing from 3.08 [2.96-3.18] to 3.86 [3.59-4.05], and the ASDR rising from 78.48 [76.09-80.74] to 91.43 [86.48-95.79]. Males consistently showed higher rates than females, and older populations bore the highest burden, with deaths and DALYs peaking in the 95+ age group in 2021. Nationally, Andorra reported the highest ASIR, ASMR, and ASDR in 2021, while Ukraine had the lowest rates. Hepatitis C and alcohol-related liver cancer were the leading contributors, with NASH showing the fastest growth. Regions with higher SDI demonstrated greater burden, highlighting healthcare access and detection disparities.

CONCLUSION

Liver cancer burden in Europe is driven by rising obesity, aging populations, lifestyle changes, and healthcare disparities, with incidence and mortality growing faster in the Europe, especially the Western region. Comprehensive strategies focusing on prevention, early detection, and equitable access to care are essential.

摘要

背景

肝癌是全球癌症相关死亡的主要原因之一。在欧洲,病毒性肝炎、酒精消费和代谢性疾病导致了这一负担。利用全球疾病负担研究2021年的数据,我们在此报告1990年至2021年欧洲的肝癌流行病学情况,描述近期趋势、地理差异以及影响疾病结局的主要风险因素。

方法

全球疾病负担研究2021年提供了1990年至2021年欧洲各地肝癌发病率、死亡率和伤残调整生命年(DALYs)的标准化数据,利用DisMod-MR 2.1等先进统计建模工具确保准确性和可比性。分析年龄标准化率(年龄标准化发病率,ASIR;年龄标准化死亡率,ASMR;以及年龄标准化DALYs率,ASDR)以及社会人口指数(SDI),使用连接点回归和局部加权回归散点平滑法(LOESS)建模来评估趋势、区域差异和关联。数据可视化使用Python工具,包括分级统计图和回归图。

结果

欧洲的肝癌负担显著增加,ASIR从1990年的3.04[2.93 - 3.14]上升至2021年的4.20[3.93 - 4.40],ASMR从3.08[2.96 - 3.18]增至3.86[3.59 - 4.05],ASDR从78.48[76.09 - 80.74]升至91.43[86.48 - 95.79]。男性的发病率始终高于女性,老年人群负担最重,2021年95岁及以上年龄组的死亡人数和DALYs达到峰值。在国家层面,安道尔在2021年报告的ASIR、ASMR和ASDR最高,而乌克兰的发病率最低。丙型肝炎和酒精相关肝癌是主要因素,非酒精性脂肪性肝炎(NASH)增长最快。SDI较高的地区负担更重,凸显了医疗服务可及性和检测方面的差异。

结论

欧洲的肝癌负担由肥胖率上升、人口老龄化、生活方式改变和医疗服务差异驱动,欧洲尤其是西部地区的发病率和死亡率增长更快。聚焦预防、早期检测和公平获得医疗服务的综合策略至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/96387ef4e8d8/ms9-87-4053-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/2be3e64652dc/ms9-87-4053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/0a923dce5914/ms9-87-4053-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/9738cbbbeb59/ms9-87-4053-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/f7355febc4b7/ms9-87-4053-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/7261bb07ef20/ms9-87-4053-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/4ee885346b20/ms9-87-4053-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/84df28a341fa/ms9-87-4053-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/96387ef4e8d8/ms9-87-4053-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/2be3e64652dc/ms9-87-4053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/0a923dce5914/ms9-87-4053-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/9738cbbbeb59/ms9-87-4053-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/f7355febc4b7/ms9-87-4053-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/7261bb07ef20/ms9-87-4053-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/4ee885346b20/ms9-87-4053-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/84df28a341fa/ms9-87-4053-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efd/12369744/96387ef4e8d8/ms9-87-4053-g008.jpg

相似文献

1
Burden of liver cancer in the European region from 1990 to 2021: a sub-analysis of the global burden of disease study.1990年至2021年欧洲地区肝癌负担:全球疾病负担研究的子分析
Ann Med Surg (Lond). 2025 May 30;87(7):4053-4065. doi: 10.1097/MS9.0000000000003433. eCollection 2025 Jul.
2
Rising incidence and clinical impact of kidney cancer in China and worldwide: a call for targeted prevention, early diagnosis, and equitable treatment.中国及全球肾癌发病率上升及其临床影响:呼吁进行针对性预防、早期诊断和公平治疗。
Transl Androl Urol. 2025 May 30;14(5):1391-1407. doi: 10.21037/tau-2024-750. Epub 2025 May 27.
3
Comprehensive age-period-cohort analysis of global pancreatitis burden and socioeconomic disparities (1990-2021).全球胰腺炎负担及社会经济差异的综合年龄-时期-队列分析(1990 - 2021年)
BMC Gastroenterol. 2025 Sep 1;25(1):630. doi: 10.1186/s12876-025-04222-1.
4
Burden of knee osteoarthritis in China and globally: 1990-2045.中国及全球膝关节骨关节炎负担:1990 - 2045年
BMC Musculoskelet Disord. 2025 Jul 1;26(1):582. doi: 10.1186/s12891-025-08858-8.
5
National and subnational burden of brain and central nervous system cancers in China and global from 1990 to 2021: results from the global burden of disease study 2021.1990年至2021年中国及全球脑癌和中枢神经系统癌症的国家和次国家负担:全球疾病负担研究2021的结果
Arch Public Health. 2025 Jul 28;83(1):195. doi: 10.1186/s13690-025-01683-4.
6
The global burden of stroke attributable to high alcohol use from 1990 to 2021: An analysis for the global burden of disease study 2021.1990年至2021年因大量饮酒导致的全球中风负担:全球疾病负担研究2021的分析
PLoS One. 2025 Jul 14;20(7):e0328135. doi: 10.1371/journal.pone.0328135. eCollection 2025.
7
Global, regional, and national burden of maternal disorders, 1990-2021: a systematic analysis from the global burden of disease study 2021.1990 - 2021年全球、区域和国家孕产妇疾病负担:全球疾病负担研究2021的系统分析
BMC Public Health. 2025 Jul 29;25(1):2576. doi: 10.1186/s12889-025-23814-w.
8
Global, regional, and national burdens of eating disorders from 1990 to 2021 and projection to 2035.1990年至2021年全球、区域和国家饮食失调负担及到2035年的预测。
Front Nutr. 2025 Aug 11;12:1595390. doi: 10.3389/fnut.2025.1595390. eCollection 2025.
9
Global epidemiological trends in prostate cancer burden: a comprehensive analysis from Global Burden of Disease Study 2021.前列腺癌负担的全球流行病学趋势:来自《2021年全球疾病负担研究》的综合分析
Transl Androl Urol. 2025 May 30;14(5):1238-1252. doi: 10.21037/tau-2025-103. Epub 2025 May 27.
10
Hepatoblastoma regional trends: dynamic SDI & joinpoint regression analysis.肝母细胞瘤的区域趋势:动态社会人口指数与连接点回归分析
BMC Cancer. 2025 Jul 5;25(1):1148. doi: 10.1186/s12885-025-14566-2.

本文引用的文献

1
Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data.基于 GBD、CI5plus 和世卫组织数据预测 2040 年肝癌的流行趋势和负担。
Sci Rep. 2024 Nov 15;14(1):28131. doi: 10.1038/s41598-024-77658-2.
2
Global epidemiology of liver cancer 2022: An emphasis on geographic disparities.全球 2022 年肝癌流行病学:重点关注地理差异。
Chin Med J (Engl). 2024 Oct 5;137(19):2334-2342. doi: 10.1097/CM9.0000000000003264. Epub 2024 Sep 3.
3
Changes in the epidemiological trends of primary liver cancer in the Asia-Pacific region.
亚太地区原发性肝癌的流行病学趋势变化。
Sci Rep. 2024 Aug 22;14(1):19544. doi: 10.1038/s41598-024-70526-z.
4
Attributable liver cancer deaths and disability-adjusted life years in China and worldwide: profiles and changing trends.归因于肝癌的死亡人数和全球及中国的伤残调整生命年:概况和变化趋势。
Cancer Biol Med. 2024 Jul 16;21(8):679-91. doi: 10.20892/j.issn.2095-3941.2024.0149.
5
Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.全球 204 个国家和地区及 811 个亚级行政区 1990 年至 2021 年 288 种死因及预期寿命的归因分析:全球疾病负担研究 2021 系统分析。
Lancet. 2024 May 18;403(10440):2100-2132. doi: 10.1016/S0140-6736(24)00367-2. Epub 2024 Apr 3.
6
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.肝细胞癌病因及流行病学的变化:亚洲及全球情况
J Liver Cancer. 2024 Mar;24(1):62-70. doi: 10.17998/jlc.2024.03.13. Epub 2024 Mar 25.
7
Inequities in primary liver cancer in Europe: The state of play.欧洲原发性肝癌的不平等现象:现状。
J Hepatol. 2024 Apr;80(4):645-660. doi: 10.1016/j.jhep.2023.12.031. Epub 2024 Jan 17.
8
Changing epidemiology, global trends and implications for outcomes of NAFLD.非酒精性脂肪性肝病的流行病学变化、全球趋势及其对结局的影响。
J Hepatol. 2023 Sep;79(3):842-852. doi: 10.1016/j.jhep.2023.04.036. Epub 2023 May 9.
9
Global burden of liver disease: 2023 update.全球肝病负担:2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
10
The latest global burden of liver cancer: A past and present threat.最新的全球肝癌负担:过去与现在的威胁。
Clin Mol Hepatol. 2023 Apr;29(2):355-357. doi: 10.3350/cmh.2023.0070. Epub 2023 Mar 9.